COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG

Information

  • Patent Application
  • 20230159537
  • Publication Number
    20230159537
  • Date Filed
    September 24, 2021
    2 years ago
  • Date Published
    May 25, 2023
    a year ago
Abstract
The present disclosure relates to a pyrazolo[3,4-d]pyrimidine compound, a preparation method thereof, and use thereof in the preparation of an anti-tumor drug. This class of compound has an inhibitory effect on FGFR1-3 and exhibits an anti-proliferation effect on NCI-H1581 and SNU-16 cancer cell lines.
Description
TECHNICAL FIELD

The present disclosure relates to the technical field of pharmacy, and in particular to a 2H-pyrazolo[3,4-d]pyrimidine derivative, a preparation method thereof, and use thereof in the preparation of an anti-cancer drug.


BACKGROUND ART

Fibroblast growth factor receptors (FGFRs) are members of the receptor tyrosine kinase (RTK) family and are receptor protein tyrosine kinases (RPTKs), including four highly-conserved transmembrane tyrosine kinases: FGFR1, FGFR2, FGFR3, and FGFR4. A signaling pathway of FGFR is that a ligand binds to a receptor to induce FGFR dimerization, thereby causing cascade activation of downstream signaling pathways such as Ras-MAPK, PI3K-Akt, STAT, and PLCγ. FGFRs play important roles in a variety of cell functions, such as cell proliferation and differentiation, and biological processes including development, angiogenesis, homeostasis, and wound repair. According to research surveys(1-3), 7.1% of cancer patients have FGFR abnormalities. For example, the FGFR1 amplification occurred most in squamous non-small cell lung cancer (NSCLC) patients with a proportion of 20%, which was 10% in breast cancer patients, 5% in ovarian cancer patients, and 3% in bladder cancer patients. Currently, FGFR2 mutations have been found in gastric cancer (10%), endometrial cancer (12%), squamous NSCLC (5%), and triple-negative breast cancer (TNBC) (4%); and FGFR3 mutations are well known in bladder cancer (50% to 60%) and myeloma (15% to 20%). Aberrant FGF19/FGFR4 signaling is closely associated with hepatocellular carcinoma (HCC). Therefore, the development of a novel selective FGFR inhibitor to block the FGF/FGFR signaling pathway presents a promising therapeutic strategy for FGFR-associated cancer(4-5).


Researchers are committed to developing an FGFR inhibitor as a novel anti-cancer agent for the treatment of FGFR-associated cancer. Several multi-targeted tyrosine kinase inhibitors (TKIs) are initially used to treat FGFR abnormality-associated cancer(6), such as dovitinib (TKI-258), lucitanib (E-3810)(7), nintedanib (BIBF-1120)(8), and ponatinib (AP-24534)(9). These FGFR inhibitors developed early are non-selective(10). Subsequently, several TKIs selective for FGFR with various scaffolds are developed. Some TKIs are currently in different stages of clinical research, such as AZD-4547 (phase III)(11), BGJ-398 (phase II)(12), LY-2874455 (phase II)(13), and JNJ-42756493 (phase II)(14), and these selective FGFR inhibitors are ATP-competitive inhibitors that bind to an active form of FGFR. In addition, FGFR inhibitors developed by many pharmaceutical chemistry laboratories have been reported.(15-21).


SUMMARY

The technical problems to be solved/objectives to be achieved by the present disclosure at least include: overcoming the defects in the prior art and providing a 2H-pyrazolo[3,4-d]pyrimidine derivative, a preparation method thereof, and use thereof in the preparation of an anti-cancer drug.


In order to achieve the above objectives, the present disclosure discloses the following technical solutions:


The present disclosure provides a compound of formula I or a pharmaceutically acceptable salt thereof:




embedded image


where Ar is any one selected from the group consisting of a substituted aryl and a substituted heterocyclic group;


R is any structure selected from the group consisting of H, alkyl, aryl, —CF3, and an alkyl tertiary amine; and


Linker is any one selected from the group consisting of alkyl, alkoxyl, a heteroatom substituent, and a substituted N-heterocyclic ring.


In some embodiments, the Ar is




embedded image


embedded image


embedded image


In some embodiments, the R is H, CF3, (CH3)2NCH2, or CH3.


In some embodiments, the Linker is




embedded image


In some embodiments, the compound is one selected from the group consisting of compound 1 to compound 40:




embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


embedded image


The present disclosure also provides a preparation method of the compound or the pharmaceutically acceptable salt thereof according to the above technical solution, with a synthetic route as follows:




embedded image


In some embodiments, the preparation method may include the following steps:


subjecting a compound with a structure shown in formula a and a compound with a structure shown in formula b to a Mitsunobu reaction at room temperature for 4 h to obtain a compound with a structure shown in formula c;


subjecting the compound with the structure shown in formula c and a compound with a structure shown in formula d to a Suzuki coupling reaction at 80° C. to obtain a compound with a structure shown in formula e;


subjecting the compound with the structure shown in formula e and trifluoroacetic acid (TFA) to a deprotection reaction at 0° C. to obtain a compound with a structure shown in formula f; and


subjecting the compound with the structure shown in formula f to an acylation reaction at room temperature to obtain the compound with a structure shown in formula I;




embedded image


The present disclosure also provides use of the compound or the pharmaceutically acceptable salt thereof according to the above technical solution in the preparation of an tumor cell proliferation inhibitor, where a tumor cell is an FGFR abnormality-associated tumor cell.


In some embodiments, the tumor cell includes NCI-H1581 or SNU-16.


The present disclosure also provides use of the compound or the pharmaceutically acceptable salt thereof according to the above technical solution in blocking a fibroblast growth factor (FGF)/FGFR signaling pathway in a tumor cell, where the tumor cell is an FGFR abnormality-associated tumor cell.


In some embodiments, the tumor cell includes NCI-H1581 or SNU-16.


The present disclosure also provides a pharmaceutical composition including the compound or the pharmaceutically acceptable salt thereof according to the above technical solution, where the pharmaceutical composition further includes one or more pharmaceutically acceptable excipients; and


a dosage form of the pharmaceutical composition is any pharmaceutically acceptable dosage form.


The present disclosure also provides use of the compound or the pharmaceutically acceptable salt thereof according to the above technical solution or the pharmaceutical composition according to the above technical solution in the preparation of a drug for treating and/or preventing a cancer.


In some embodiments, the cancer is an FGFR abnormality-associated cancer.


The present disclosure also provides use of the pharmaceutical composition according to the above technical solution in the preparation of an irreversible pan-FGFR inhibitor.


The present disclosure also provides a method for treating a cancer, including the following step:


administering an anti-cancer drug to a patient through oral administration or intraperitoneal injection,


where the anti-cancer drug includes the compound or the pharmaceutically acceptable salt thereof according to the above technical solution.


In some embodiments, the anti-cancer drug includes the compound 10 or the compound 36.


In some embodiments, the anti-cancer drug is administered at a dose of 50 mg/kg or 100 mg/kg; and


the dose is calculated according to a dosage of the compound 10 or the compound 36.


In some embodiments, when the anti-cancer drug includes the compound 10, the anti-cancer drug is administered orally.


In some embodiments, when the anti-cancer drug includes the compound 36, the anti-cancer drug is administered through intraperitoneal injection.


In the present disclosure, the term “pharmaceutically acceptable adjuvant” includes pharmaceutically acceptable carriers, excipients, diluents, and the like, which are compatible with the active pharmaceutical ingredients. The preparation of a pharmaceutical formulation with a pharmaceutically acceptable adjuvant is well known to those of ordinary skill in the art.


In the present disclosure, the pharmaceutical composition may be combined with a pharmaceutically acceptable adjuvant (such as a carrier, an excipient, a diluent, or the like well known to those of ordinary skill in the art) to prepare various formulations, in further embodiments, the formulations include solid formulations and liquid preparations, such as tablets, pills, capsules, powders, suspensions, granules, syrups, emulsions, suspensions, and various sustained-release dosage forms, in some embodiments, the formulations is administered orally.





BRIEF DESCRIPTION OF DRAWINGS


FIGS. 1A and 1B show that the compound 10 inhibits the activation of FGFR1 and a downstream signaling pathway thereof in NCI-H1581 cells and inhibits the activation of FGFR2 and a downstream signaling pathway thereof in SNU-16 cells in a concentration gradient-dependent manner, where FIG. 1A shows the inhibition on the activation of the FGFR1 and the downstream signaling pathway thereof in NCI-H1581 cells, and FIG. 1B shows the inhibition on the activation of the FGFR2 and the downstream signaling pathway thereof in SNU-16 cells;



FIGS. 2A and 2B show that the compound 36 inhibits the activation of FGFR1 and a downstream signaling pathway thereof in NCI-H1581 cells and inhibits the activation of FGFR2 and a downstream signaling pathway thereof in SUN-16 cells in a concentration gradient-dependent manner, where FIG. 2A shows the inhibition on the activation of the FGFR1 and the downstream signaling pathway thereof in NCI-H1581 cells, and FIG. 2B shows the inhibition on the activation of the FGFR2 and the downstream signaling pathway thereof in SUN-16 cells;



FIGS. 3A, 3B, 3C and 3D show tumor volume curves (FIG. 3A), a tumor weight statistics chart after 26 d of treatment (FIG. 3B), body weight change curves during a treatment process (FIG. 3C), and a picture of tumors after 26 d of treatment (FIG. 3D) in a tumor model subcutaneously transplanted with NCI-H1581 tumor cells under the tumor proliferation inhibition of the compound 10; and



FIGS. 4A, 4B, 4C, 4D and 4E show tumor volume change curves (FIG. 4A), a tumor weight statistics chart after 26 d of treatment (FIG. 4B), body weight change curves during a treatment process (FIG. 4C), a picture of tumors after 26 d of treatment (FIG. 4D), and phosphorylation levels of FGFR1 in tissues of different treatments detected by immunohistochemistry (IHC) (FIG. 4E) in a tumor model subcutaneously transplanted with NCI-H1581 tumor cells under the tumor proliferation inhibition of the compound 36.





DETAILED DESCRIPTION OF THE EMBODIMENTS

Unless otherwise defined, the technical terms used in the following examples have the same meanings as commonly understood by those skilled in the art to which the present disclosure belongs. Unless otherwise specified, in the following examples, the test reagents used are all conventional biochemical reagents, and the test methods are all conventional methods.


The present disclosure will be described in detail below with reference to the examples.


Example 1: Preparation of Compound 1



embedded image


A specific preparation method was as follows:


1) Preparation of Compound (1-1)




embedded image


3-Bromo-1H-pyrazolo[3,4-d]pyrimidin-4-amine (500 mg, 2.34 mmol) was dissolved in dry tetrahydrofuran (THF) (23 mL), and then triphenylphosphine (TPP) (2.08 g, 7.94 mmol) and 1-Boc-3-azetidinemethanol were added; diisopropyl azodiformate (DIAD) (1.60 g, 7.94 mmol) was added dropwise at 0° C. under the protection of argon, then the temperature was slowly raised to room temperature, and a reaction was further allowed for 4 h; and a reaction solution was spin-dried and purified by column chromatography (petroleum ether:ethyl acetate=5:1 to 2:1) to obtain the compound 1-1 (yellow oily liquid, 685 mg, 69%).


Nuclear magnetic resonance (NMR) test results of the compound 1-1 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.06 (s, 1H), 7.96-7.87 (m, 6H), 7.64-7.45 (m, 9H), 4.48 (d, J=7.3 Hz, 2H), 3.97 (t, J=8.5 Hz, 2H), 3.88-3.74 (m, 2H), 3.19-2.98 (m, 1H), 1.41 (s, 9H). 13C NMR (100 MHz, CDCl3) δ 163.1, 163.0, 156.2, 155.9, 154.6, 154.5, 133.4, 133.4, 133.3, 133.3, 132.4, 132.3, 132.2, 128.8, 128.7, 128.7, 128.6, 128.6, 128.5, 128.4, 127.8, 127.4, 120.9, 107.1, 79.3, 52.9, 51.5, 49.7, 28.8, 28.4, 21.7, 14.2. HRMS (ESI) calculated for C32H32BrN6NaO2P+: 665.1400, found 665.1402.


2) Preparation of Compound (1-2)




embedded image


The compound 1-1 (5.01 mg, 6.74 mmol) and 3,5-dimethoxyphenylboronic acid (1.59 g, 8.76 mmol) were dissolved in a mixed solution of 1,4-dioxane and water (9 mL, v:v=3:1), and then potassium carbonate (1.87 g, 13.5 mmol) and Pd(PPh3)4 (778 mg, 0.674 mmol) were added; a resulting system was argon replaced three times, and then heated to 80° C. in an oil bath to undergo a reaction overnight; and after the reaction was completed, a resulting reaction system was washed with saturated sodium chloride (270 mL) and then subjected to extraction with ethyl acetate (90 mL), and a resulting organic phase was dried, concentrated, and purified by column chromatography (dichloromethane (DCM):methanol=70:1 to 30:1) to obtain the compound 1-2 (yellow oily liquid, 4.3 g, 60%).


NMR test results of the compound 1-2 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.06 (d, J=3.2 Hz, 1H), 7.89-7.71 (m, 6H), 7.56-7.40 (m, 11H), 6.70-6.41 (m, 1H), 4.58 (dd, J=7.3, 3.2 Hz, 2H), 4.11-3.96 (m, 2H), 3.92-3.84 (m, 2H), 3.76 (d, J=3.1 Hz, 6H), 3.26-3.07 (m, 1H), 1.41 (d, J=3.1 Hz, 9H). 13C NMR (100 MHz, CDCl3) δ 163.9, 163.9, 163.5, 163.4, 160.3, 156.3, 156.3, 155.2, 154.7, 146.1, 135.6, 134.2, 133.5, 133.4, 133.4, 133.3, 132.3, 132.2, 132.0, 132.0, 132.0, 1292, 128.6, 128.6, 128.5, 128.5, 128.4, 128.4, 128.2, 128.2, 127.8, 107.9, 100.6, 79.3, 77.4, 55.3, 49.5, 28.9, 28.4, 24.5. HRMS (ESI) calculated for C40H41N6NaO4P+: 723.2819, found 723.2822.


3) Preparation of Compound (1-3)




embedded image


At 0° C., the compound 1-2 (450 mg, 0.587 mmol) was dissolved in DCM (5 mL), and then TFA (5 mL) was slowly added dropwise, after 30 min the reaction was completed; adjusting alkali of a resulting reaction solution was conducted with saturated NaHCO3, and a resulting organic phase was concentrated to dry to obtain a brown-yellow oily intermediate. At 0° C., the intermediate was dissolved in 5 mL of DCM, then triethylamine (TEA) (98.2 μL, 0.704 mmol) was added, and then acryloyl chloride (52.2 μL, 0.646 mmol) was added dropwise; and a reaction was further allowed for 1 h at room temperature; and when it was monitored by thin layer chromatography (TLC) that the reaction was completed, a resulting reaction system was washed with saturated NaCl and then subjected to extraction with ethyl acetate, and a resulting organic phase was dried, concentrated, and purified by column chromatography (DCM:methanol=30:1 to 10:1) to obtain the compound 1-3 (yellow oily liquid, 78 mg, 72%).


4) Preparation of compound 1-3: The compound 1-3 (100 mg, 0.189 mmol) was added to a mixed solution of acetic acid, THF, and water (3 mL, 3:1:2), and a reaction was conducted at room temperature for 18 h; and when it was monitored by TLC that the reaction was completed, a pH of a resulting reaction solution was adjusted to 7 to 8 with a saturated NaHCO3 solution (15 mL), extraction was conducted with ethyl acetate (10 mL×2), and a resulting organic phase was dried, concentrated, and purified by column chromatography (DCM:methanol=15:1 to 7:1) to obtain the compound 1-3 (yellow solid, 57.8 mg, 70%).


NMR test results of the compound 1 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 6.80 (d, J=2.3 Hz, 2H), 6.57 (t, J=2.3 Hz, 1H), 6.33 (dd, J=17.0, 1.9 Hz, 1H), 6.17 (dd, J=17.0, 10.3 Hz, 1H), 5.76-5.57 (m, 3H), 4.76-4.61 (m, 2H), 4.38-4.14 (m, 3H), 4.02 (dd, J=10.5, 5.5 Hz, 1H), 3.87 (s, 6H), 3.49-3.25 (m, 1H). 13C NMR (100 MHz, CDCl3) δ 165.7, 161.6, 157.8, 156.2, 154.7, 144.7, 134.8, 127.4, 127.2, 125.7, 106.3, 101.2, 98.4, 55.6, 53.5, 50.8, 49.4, 32.7, 29.1, 27.9. HRMS (ESI) calculated for C20H22N6NaO3+: 417.1646, found 417.1648.


Example 2: Preparation of Compound 2



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 1-Boc-3-hydroxymethylpyrrolidine, in replacement of 1-Boc-3-azetidinemethanol in the preparation method of compound (1-1). NMR test results of the compound 2 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 6.81 (d, J=2.2 Hz, 2H), 6.62-6.54 (m, 2H), 6.25 (dd, J=16.9, 2.0 Hz, 1H), 5.76 (s, 2H), 5.66 (dd, J=10.6, 2.0 Hz, 1H), 4.65 (d, J=13.3 Hz, 1H), 4.49 (t, J=7.2 Hz, 2H), 3.99 (d, J=13.7 Hz, 1H), 3.86 (s, 6H), 3.00 (t, J=12.6 Hz, 1H), 2.64-2.52 (m, 1H), 1.97-1.94 (m, 1H), 1.91 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 164.5, 161.5, 158.0, 156.0, 154.6, 144.6, 134.9, 128.5, 127.5, 106.4, 101.3, 98.3, 55.6, 50.0, 49.1, 45.7, 45.2, 39.9, 37.74 29.6, 27.9. HRMS (ESI) calculated for C2H24N6NaO3+: 431.1802, found 431.1804.


Example 3: Preparation of Compound 3



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar N-Boc-4-hydroxypiperidine, in replacement of 1-Boc-3-azetidinemethanol in the preparation method of compound (1-1). NMR test results of the compound 3 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 6.80 (d, J=2.2 Hz, 2H), 6.67-6.51 (m, 2H), 6.31 (dd, J=16.8, 1.8 Hz, 1H), 5.84-5.63 (m, 3H), 5.05 (tt, J=11.3, 4.2 Hz, 1H), 4.85 (d, J=13.4 Hz, 1H), 4.20 (d, J=13.9 Hz, 1H), 3.86 (s, 6H), 3.33 (t, J=12.7 Hz, 1H), 3.02-2.85 (m, 1H), 2.34 (t, J=11.8 Hz, 2H), 2.11 (d, J=13.0 Hz, 2H). 13C NMR (101 MHz, CDCl3) δ 161.5, 157.8, 155.8, 154.7, 154.3, 144.1, 135.1, 132.1, 131.6, 106.3, 101.1, 100.0, 98.3, 79.6, 55.7, 55.6, 52.9, 45.5, 29.7, 28.4, 26.8. HRMS (ESI) calculated for C2H24N6NaO3+: 431.1802, found 431.1805.


Example 4: Preparation of Compound 4



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar N-Boc-4-piperidinemethanol, in replacement of 1-Boc-3-azetidinemethanol in the preparation method of compound (1-1). NMR test results of the compound 4 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.34 (s, 1H), 6.80 (d, J=2.3 Hz, 2H), 6.57-6.49 (m, 2H), 6.23 (d, J=16.8 Hz, 1H), 5.89 (s, 2H), 5.64 (d, J=10.6 Hz, 1H), 4.65 (d, J=13.3 Hz, 1H), 4.33 (d, J=7.1 Hz, 2H), 3.97 (d, J=13.8 Hz, 1H), 3.85 (s, 6H), 3.00 (t, J=12.9 Hz, 1H), 2.62 (t, J=12.9 Hz, 1H), 2.33 (d, J=11.0 Hz, 1H), 1.66 (d, J=16.3 Hz, 3H), 1.33 (td, J=14.3, 7.5 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.4, 161.5, 161.5, 157.9, 156.0, 154.7, 144.3, 134.9, 127.9, 127.9, 127.4, 106.4, 101.1, 99.9, 98.2, 55.6, 51.9, 45.6, 41.8, 36.8, 30.5, 29.4. HRMS (ESI) calculated for C22H26N6NaO3+: 445.1959, found 445.1961.


Example 5: Preparation of Compound 5



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar N-Boc-4-piperidineethanol, in replacement of 1-Boc-3-azetidinemethanol in the preparation method of compound (1-1). NMR test results of the compound 5 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.38 (d, J=1.1 Hz, 1H), 6.81 (d, J=2.3 Hz, 2H), 6.57 (d, J=2.4 Hz, 1H), 6.44-6.36 (m, 2H), 5.68 (dd, J=9.6, 2.7 Hz, 1H), 4.50 (dd, J=12.8, 6.9 Hz, 2H), 3.87 (s, 7H), 3.80-3.72 (m, 2H), 3.72-3.65 (m, 1H), 3.57-3.47 (m, 2H), 3.01 (d, J=7.3 Hz, 1H), 1.65 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 166.3, 162.5, 158.7, 156.8, 155.2, 145.2, 136.0, 128.9, 128.4, 107.4, 102.1, 99.3, 56.6, 47.3, 45.6, 43.2, 36.9, 34.6, 33.5, 32.9, 32.6, 30.7, 30.4. HRMS (ESI) calculated for C23H28N6NaO3+: 459.2115, found 459.2115.


Example 6: Preparation of Compound 6



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 1-Boc-3-hydroxymethylpiperidine, in replacement of 1-Boc-3-azetidinemethanol in the preparation method of compound (1-1). NMR test results of the compound 6 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.39-8.33 (m, 1H), 6.93-6.75 (m, 2H), 6.63-6.46 (m, 2H), 6.21 (dd, J=16.9, 8.7 Hz, 1H), 5.99 (s, 2H), 5.61 (dd, J=32.0, 10.5 Hz, 1H), 4.53-4.27 (m, 3H), 3.86 (s, 6H), 3.07 (dt, J=23.7, 12.4 Hz, 1H), 2.81 (dt, J=44.0, 12.0 Hz, 1H), 2.35 (s, 1H), 1.93 (s, 1H), 1.58-1.29 (m, 2H), 1.26 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 165.5, 161.6, 157.9, 155.9, 154.7, 127.8, 127.4, 106.3, 101.3, 98.2, 55.6, 49.8, 49.7, 49.5, 46.5, 45.8, 42.7, 37.4, 36.4, 28.7, 25.2, 24.1. HRMS (ESI) calculated for C22H26N6NaO3+: 445.1959, found 445.1961.


Example 7: Preparation of Compound 7



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar tert-Butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate, in replacement of 1-Boc-3-azetidinemethanol in the preparation method of compound (1-1). NMR test results of the compound 7 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 6.80 (d, J=2.3 Hz, 2H), 6.60-6.47 (m, 2H), 6.26 (dd, J=16.8, 1.9 Hz, 1H), 5.67 (dd, J=10.5, 1.9 Hz, 1H), 4.57 (t, J=6.7 Hz, 2H), 3.85 (s, 6H), 3.62 (s, 2H), 3.49 (s, 2H), 2.96 (t, J=6.7 Hz, 2H), 2.56 (t, J=5.0 Hz, 4H). 13C NMR (100 MHz, CDCl3) δ 165.3, 161.5, 157.4, 155.1, 154.5, 144.6, 134.8, 127.9, 127.4, 106.3, 101.2, 98.2, 95.6, 56.7, 55.6, 52.6, 50.9, 45.6, 44.4, 41.8, 31.9, 29.1. HRMS (ESI) calculated for C22H27N7NaO3+: 460.2068, found 460.2072.


Example 8: Preparation of Compound 8



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 1-Boc-4-(3-hydroxypropane)piperazine, in replacement of 1-Boc-3-azetidinemethanol in the preparation method of compound (1-1). NMR test results of the compound 8 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 6.81 (d, J=2.3 Hz, 2H), 6.58-6.50 (m, 2H), 5.88 (s, 2H), 5.69 (dd, J=10.5, 1.9 Hz, 1H), 4.52 (t, J=6.9 Hz, 2H), 3.86 (s, 6H), 3.69 (d, J=6.9 Hz, 2H), 3.57 (s, 2H), 2.51 (dt, J=10.8, 6.0 Hz, 6H), 2.21 (p, J=7.0 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.3, 160.3, 154.4, 133.4, 133.3, 132.2, 132.1, 132.0, 129.0, 128.6, 128.6, 128.4, 128.1, 127.3, 127.3, 107.9, 100.5, 55.4, 55.3, 53.1, 52.5, 45.2, 26.4. HRMS (ESI) calculated for C23H29N7NaO3+: 474.2224, found 474.2226.


Example 9: Preparation of Compound 9



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 1-Boc-4-(4-hydroxybutane)piperazine, in replacement of 1-Boc-3-azetidinemethanol in the preparation method of compound (1-1). NMR test results of the compound 9 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.40-8.36 (m, 1H), 6.81 (dd, J=3.2, 2.0 Hz, 2H), 6.54 (ddd, J=17.4, 8.7, 4.1 Hz, 2H), 6.28 (dt, J=16.9, 2.5 Hz, 1H), 5.72-5.66 (m, 1H), 5.61 (s, 2H), 4.46 (s, 2H), 3.89-3.82 (m, 6H), 3.67 (s, 2H), 3.54 (s, 2H), 2.41 (s, 6H), 2.01 (s, 2H), 1.56 (s, 2H). 13C NMR (100 MHz, MeOD) δ 169.4, 166.0, 152.2, 151.70, 147.6, 145.9, 132.7, 128.5, 126.6, 106.2, 106.1, 101.5, 101.4, 96.5, 56.6, 54.7, 53.5, 51.1, 40.5, 39.1, 38.5, 35.2, 28.3, 22.7. HRMS (ESI) calculated for C24H31N7NaO3+: 488.2381, found 488.2383.


Example 10: Preparation of Compound 10



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 1-Boc-4-(5-hydroxypentane)piperazine, in replacement of 1-Boc-3-azetidinemethanol in the preparation method of compound (1-1). NMR test results of the compound 10 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 6.82-6.80 (m, 2H), 6.58-6.55 (m, 1H), 6.53 (d, J=10.4 Hz, 1H), 6.27 (d, J=16.7 Hz, 1H), 5.68 (d, J=10.6 Hz, 1H), 5.61 (s, 2H), 4.43 (s, 2H), 3.86 (s, 6H), 3.67 (s, 2H), 3.53 (s, 2H), 2.42-2.38 (m, 4H), 2.34-2.30 (m, 2H), 2.02-1.96 (m, 2H), 1.54 (d, J=7.4 Hz, 2H), 1.39 (d, J=6.9 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.3, 161.6, 157.7, 155.9, 154.3, 144.0, 135.1, 127.7, 127.5, 106.4, 101.1, 100.0, 98.3, 58.2, 55.6, 53.4, 52.7, 47.1, 45.7, 41.8, 40.5, 29.6, 29.3, 26.2, 24.5. HRMS (ESI) calculated for C25H33N7NaO3+: 502.2537, found 502.2539.


Example 11: Preparation of Compound 11



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 1-Boc-4-(6-hydroxyhexane)piperazine, in replacement of 1-Boc-3-azetidinemethanol in the preparation method of compound (1-1). NMR test results of the compound 11 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.34 (d, J=1.3 Hz, 1H), 6.81 (dd, J=2.3, 1.3 Hz, 2H), 6.61-6.52 (m, 2H), 6.29 (dt, J=16.9, 1.6 Hz, 1H), 6.00 (s, 2H), 5.69 (dt, J=10.5, 1.6 Hz, 1H), 4.43 (t, J=7.3 Hz, 2H), 3.86 (d, J=1.3 Hz, 6H), 3.69 (t, J=5.0 Hz, 2H), 3.56 (t, J=4.9 Hz, 2H), 2.42 (t, J=5.0 Hz, 4H), 2.33 (t, J=7.6 Hz, 2H), 1.97 (t, J=7.2 Hz, 2H), 1.54-1.45 (m, 2H), 1.38 (t, J=4.3 Hz, 4H). 13C NMR (100 MHz, CDCl3) δ 165.3, 161.5, 157.8, 155.3, 154.1, 144.2, 135.0, 135.0, 127.9, 127.5, 127.5, 106.4, 106.4, 101.1, 98.2, 58.3, 55.6, 53.4, 52.7, 47.2, 45.7, 41.8, 29.7, 27.0, 26.6, 26.5. HRMS (ESI) calculated for C26H35N7NaO3+: 516.2694, found 516.2696.


Example 12: Preparation of Compound 12



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 1-Boc-4-(7-hydroxyheptane)piperazine, in replacement of 1-Boc-3-azetidinemethanol in the preparation method of compound (1-1). NMR test results of the compound 12 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.38 (d, J=2.8 Hz, 1H), 6.82 (t, J=2.5 Hz, 2H), 6.62-6.50 (m, 2H), 6.33-6.23 (m, 1H), 5.77-5.56 (m, 3H), 4.42 (s, 2H), 3.86 (d, J=2.8 Hz, 6H), 3.70 (s, 2H), 3.57 (s, 2H), 2.50-2.37 (m, 4H), 2.33 (s, 2H), 1.96 (s, 2H), 1.47 (s, 2H), 1.33 (d, J=27.0 Hz, 6H). 13C NMR (101 MHz, CDCl3) δ 165.6, 161.8, 158.1, 156.1, 154.5, 144.3 135.5, 135.5, 128.1, 127.8, 106.7, 101.4, 101.4, 98.6, 58.7, 55.9, 53.7, 53.1, 47.5, 46.0, 42.2, 30.0, 29.9, 29.3, 27.6, 26.9, 26.8. HRMS (ESI) calculated for C27H37N7NaO3+: 530.2850, found 530.2852.


Example 13: Preparation of Compound 13



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 3,4-methylenephenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 13 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 7.16 (d, J=2.7 Hz, 1H), 6.97 (d, J=7.9 Hz, 1H), 6.62-6.49 (m, 1H), 6.28 (dd, J=16.9, 2.0 Hz, 1H), 6.06 (s, 2H), 5.86-5.65 (m, 3H), 4.42 (t, J=7.2 Hz, 2H), 3.70 (d, J=7.5 Hz, 2H), 3.55 (t, J=5.1 Hz, 2H), 2.43 (t, J=4.9 Hz, 4H), 2.35 (t, J=7.6 Hz, 2H), 1.99 (td, J=16.9, 15.0, 9.4 Hz, 2H), 1.79-1.14 (m, 6H). 13C NMR (100 MHz, CDCl3) δ 165.2, 157.8, 155.7, 154.2, 148.6, 148.5, 143.8, 127.4, 127.1, 122.1, 109.0, 108.9, 101.6, 101.5, 98.2, 58.1, 53.3, 52.7, 46.9, 45.6, 41.7, 29.5, 26.1, 24.5. HRMS (ESI) calculated for C24H29N7NaO3+: 4860.2224, found 4860.2226.


Example 14: Preparation of Compound 14



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar benzofuran-2-boronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 14 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.39 (s, 1H), 7.68 (dd, J=7.3, 1.5 Hz, 1H), 7.59-7.55 (m, 1H), 7.40-7.32 (m, 3H), 6.53 (dd, J=16.8, 10.6 Hz, 1H), 6.28 (dd, J=16.9, 1.9 Hz, 1H), 5.68 (dd, J=10.6, 2.0 Hz, 1H), 4.46 (t, J=7.2 Hz, 2H), 3.69 (s, 2H), 3.55 (s, 2H), 2.44 (s, 4H), 2.36 (t, J=7.6 Hz, 2H), 2.01 (p, J=7.4 Hz, 2H), 1.57 (q, J=7.6 Hz, 2H), 1.44-1.36 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 165.3, 163.8, 157.6, 156.0 154.4, 149.5, 134.7, 128.3, 127.8, 127.4, 125.1, 124.0, 121.7, 111.0, 104.3, 97.9, 58.1, 53.3, 52.7, 47.3, 45.6, 41.7, 29.5, 26.1, 24.4. HRMS (ESI) calculated for C25H29N7NaO2+: 482.2269, found 482.2271.


Example 15: Preparation of Compound 15



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar p-methoxyboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 15 were as follows:



1H NMR (400 MHz, MeOD) δ 8.24 (s, 1H), 7.61 (d, J=8.6 Hz, 2H), 7.18-7.06 (m, 2H), 6.82-6.64 (m, 1H), 6.19 (dd, J=16.7, 2.0 Hz, 1H), 5.74 (dd, J=10.6, 1.9 Hz, 1H), 4.41 (t, J=6.8 Hz, 2H), 3.88 (s, 3H), 3.62 (s, 4H), 2.48 (s, 4H), 2.39 (s, 2H), 1.96 (q, J=7.3 Hz, 2H), 1.60-1.52 (m, 2H), 1.35 (q, J=7.9 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.3, 157.7, 155.9, 155.9, 154.4, 143.6, 140.4, 133.9, 132.5, 129.6, 127.8, 126.7, 125.9, 124.7, 64.1, 58.2, 53.4, 52.7, 48.6, 47.1, 29.5, 26.0, 24.5, 15.5. HRMS (ESI) calculated for C24H31N7NaO2+: 472.2426, found 472.2428.


Example 16: Preparation of Compound 16



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 4-acetylaminophenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 16 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.24 (d, J=1.3 Hz, 1H), 8.01 (s, 1H), 7.54-7.43 (m, 3H), 6.72 (dd, J=16.9, 10.7 Hz, 1H), 6.18 (dt, J=16.8, 1.7 Hz, 1H), 5.73 (dt, J=10.6, 1.7 Hz, 1H), 4.43 (t, J=6.7 Hz, 2H), 3.60 (q, J=6.7, 4.6 Hz, 4H), 2.46 (d, J=5.2 Hz, 4H), 2.37 (t, J=7.6 Hz, 2H), 2.16 (d, J=1.4 Hz, 3H), 1.97 (t, J=7.4 Hz, 2H), 1.57 (dd, J=11.0, 4.7 Hz, 2H), 1.34 (p, J=7.6 Hz, 2H). 13C NMR (100 MHz, MeOD) δ 170.6, 165.9, 158.4, 155.4, 153.8, 144.4, 139.14, 133.2, 129.6, 127.3, 127.3, 123.7, 120.4, 120.1, 100.0, 97.6, 57.6, 52.8, 52.3, 45.0, 41.3, 28.9, 25.3, 23.9, 22.4. HRMS (ESI) calculated for C25H32N8NaO2+: 472.2426, found 472.2428.


Example 17: Preparation of Compound 17



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that equimolar 4-trifluoromethoxyphenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 17 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.27 (s, 1H), 7.70 (t, J=7.6 Hz, 1H), 7.63 (d, J=10.6 Hz, 1H), 7.49-7.42 (m, 1H), 7.35 (dd, J=7.8, 5.3 Hz, 1H), 6.73 (dd, J=16.8, 10.7 Hz, 1H), 6.18 (dd, J=16.8, 1.9 Hz, 1H), 5.73 (dd, J=10.7, 2.0 Hz, 1H), 4.44 (t, J=6.8 Hz, 2H), 3.61 (d, J=5.4 Hz, 4H), 2.50-2.37 (m, 4H), 2.35 (d, J=7.7 Hz, 2H), 1.99 (q, J=7.1 Hz, 2H), 1.59-1.55 (m, 2H), 1.35 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 166.2, 158.5, 156.8, 155.4, 150.6, 143.3, 136.3, 131.8, 128.6, 128.4, 127.6, 122.3, 121.9, 120.1, 99.2, 59.1, 54.3, 53.6, 48.1, 46.6, 42.8, 30.4, 27.1, 25.4. HRMS (ESI) calculated for C24H28F3N7NaO2+: 526.2143, found 526.2145.


Example 18: Preparation of Compound 18



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 2-naphthaleneboronic acid in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 18 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.41 (s, 1H), 8.17 (s, 1H), 8.03 (d, J=8.4 Hz, 1H), 7.93 (dd, J=9.3, 3.6 Hz, 2H), 7.82 (d, J=8.4 Hz, 1H), 7.58 (dd, J=6.2, 3.2 Hz, 2H), 6.51 (dd, J=16.8, 10.5 Hz, 1H), 6.27 (d, J=16.8 Hz, 1H), 5.67 (d, J=10.7 Hz, 1H), 4.49 (t, J=7.2 Hz, 2H), 3.68 (s, 2H), 3.51 (d, J=15.2 Hz, 2H), 2.37 (dd, J=19.5, 12.3 Hz, 6H), 2.04 (dd, J=14.6, 7.4 Hz, 2H), 1.57 (dd, J=14.7, 7.5 Hz, 2H), 1.42 (dd, J=14.9, 7.9 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.28, 157.63, 155.97, 154.54, 149.88, 142.42, 135.37, 135.35, 130.91, 127.75, 127.50, 127.24, 126.68, 121.64, 121.38, 121.00, 118.73, 98.31, 58.16, 53.43, 52.73, 47.17, 45.72, 41.87, 29.53, 26.24, 24.52. HRMS (ESI) calculated for C27H31N7NaO+: 492.2482, found 492.2484.


Example 19: Preparation of Compound 19



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 4-methylnaphthaleneboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 19 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.37 (s, 1H), 8.10 (d, J=8.4 Hz, 1H), 7.91 (d, J=8.3 Hz, 1H), 7.63-7.41 (m, 4H), 6.52 (dd, J=16.8, 10.5 Hz, 1H), 6.26 (dd, J=16.8, 1.7 Hz, 1H), 5.67 (dd, J=10.5, 1.7 Hz, 1H), 4.50 (t, J=7.1 Hz, 2H), 3.66 (s, 2H), 3.49 (d, J=16.9 Hz, 2H), 2.78 (s, 3H), 2.36 (dd, J=19.3, 12.0 Hz, 6H), 2.13-1.98 (m, 2H), 1.57 (dt, J=14.9, 7.6 Hz, 2H), 1.42 (dt, J=15.0, 7.6 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.27, 159.72, 157.75, 155.67, 154.23, 144.16, 134.49, 130.52, 127.93, 127.88, 127.43, 120.40, 120.11, 115.46, 114.30, 98.54, 98.31, 63.68, 58.15, 53.31, 52.69, 47.03, 41.74, 29.71, 29.54, 26.11, 24.50, 24.04. HRMS (ESI) calculated for C28H33N7NaO+: 570.1587, found 570.1590.


Example 20: Preparation of Compound 20



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 4-bromonaphthaleneboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 20 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 8.11 (d, J=8.4 Hz, 1H), 7.92 (d, J=8.3 Hz, 1H), 7.64-7.42 (m, 4H), 6.53 (dd, J=16.8, 10.5 Hz, 1H), 6.27 (dd, J=16.8, 1.7 Hz, 1H), 5.68 (dd, J=10.5, 1.7 Hz, 1H), 4.51 (t, J=7.1 Hz, 2H), 3.67 (s, 2H), 3.50 (d, J=17.0 Hz, 2H), 2.37 (dd, J=19.3, 12.0 Hz, 6H), 2.13-1.99 (m, 2H), 1.58 (dt, J=14.9, 7.6 Hz, 2H), 1.43 (dt, J=15.0, 7.6 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.16, 157.62, 157.55, 155.88, 154.26, 149.40, 134.60, 128.22, 127.80, 127.72, 127.32, 125.04, 123.91, 121.64, 121.60, 110.91, 104.17, 99.87, 97.77, 58.01, 53.21, 52.59, 47.20, 45.47, 41.63, 29.34, 24.31. HRMS (ESI) calculated for C27H30BrN7NaO+: 570.1587, found 570.1590.


Example 21: Preparation of Compound 21



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 2,5-dimethoxyphenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 21 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.35 (s, 1H), 7.07 (s, 1H), 7.02 (d, J=8.6 Hz, 2H), 6.56 (dd, J=16.8, 10.6 Hz, 1H), 6.28 (d, J=16.8 Hz, 1H), 5.70 (d, J=7.6 Hz, 1H), 4.44 (t, J=7.1 Hz, 2H), 3.81 (d, J=11.0 Hz, 6H), 3.69 (s, 2H), 3.55 (s, 2H), 2.47-2.32 (m, 6H), 2.03 (dd, J=14.0, 7.0 Hz, 2H), 1.61-1.52 (m, 2H), 1.41 (dd, J=14.7, 7.6 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.28, 158.41, 155.55, 154.40, 153.90, 150.49, 140.79, 127.83, 127.47, 123.11, 117.10, 116.10, 113.43, 100.37, 58.17, 56.76, 55.85, 53.35, 52.72, 47.06, 45.66, 41.80, 29.55, 26.21. HRMS (ESI) calculated for C25H33N7NaO3+: 502.2537, found 502.2539.


Example 22: Preparation of Compound 22



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 3,4-dimethoxyphenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 22 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.39 (s, 1H), 7.27 (s, 1H), 6.89 (s, 2H), 6.64-6.50 (m, 1H), 6.29 (d, J=16.6 Hz, 1H), 5.70 (d, J=10.2 Hz, 3H), 4.43 (d, J=6.9 Hz, 2H), 3.94 (s, 3H), 3.91 (s, 3H), 3.69 (s, 2H), 3.56 (s, 2H), 2.38 (dd, J=22.3, 15.1 Hz, 6H), 2.03-1.98 (m, 2H), 1.57 (d, J=6.9 Hz, 2H), 1.40 (d, J=7.0 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.34, 165.29, 157.82, 155.94, 155.91, 155.87, 154.22, 154.05, 153.99, 144.18, 138.75, 128.59, 127.92, 127.42, 105.53, 98.33, 61.03, 58.18, 56.33, 53.39, 52.70, 47.06, 29.61, 26.19, 24.53. HRMS (ESI) calculated for C25H33N7NaO3+: 502.2537, found 502.2539.


Example 23: Preparation of Compound 23



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 3,4,5-trimethoxyphenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 23 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.30 (s, 1H), 6.82 (d, J=1.3 Hz, 2H), 6.47 (ddd, J=16.8, 10.5, 1.3 Hz, 1H), 6.19 (dt, J=16.8, 1.6 Hz, 1H), 5.87 (s, 2H), 5.60 (dt, J=10.5, 1.6 Hz, 1H), 4.36 (t, J=7.3 Hz, 2H), 3.86 (d, J=1.3 Hz, 6H), 3.83 (d, J=1.3 Hz, 3H), 3.60 (t, J=5.0 Hz, 2H), 3.47 (t, J=5.0 Hz, 2H), 2.33 (t, J=5.1 Hz, 4H), 2.27 (d, J=7.5 Hz, 2H), 1.93 (q, J=7.6 Hz, 2H), 1.49 (t, J=7.6 Hz, 2H), 1.33 (d, J=7.6 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.2, 158.0, 155.8, 154.2, 153.9, 144.1, 138.8, 128.6, 128.6, 128.4, 127.7, 127.5, 105.6, 98.3, 61.0, 58.2, 56.3, 53.4, 52.7, 47.0, 45.7, 41.9, 29.7, 29.6, 26.3, 24.5. HRMS (ESI) calculated for C26H35N7NaO4+: 532.2643, found 536.2645.


Example 24: Preparation of Compound 24



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 3-trifluoromethylphenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 24 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.37 (s, 1H), 7.68-7.54 (m, 3H), 7.33 (d, J=6.5 Hz, 1H), 6.59-6.47 (m, 1H), 6.25 (dd, J=16.8, 4.6 Hz, 1H), 5.95-5.59 (m, 3H), 4.43 (d, J=6.6 Hz, 2H), 3.64 (d, J=9.2 Hz, 2H), 3.52 (s, 2H), 2.39 (d, J=5.7 Hz, 4H), 2.32 (d, J=7.3 Hz, 2H), 1.98 (q, J=7.1 Hz, 2H), 1.56 (s, 2H), 1.42-1.32 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 165.3, 157.7, 155.8, 154.5, 149.8, 142.5, 135.3, 130.9, 127.7, 127.5, 126.7, 121.4, 121.0, 98.3, 58.1, 53.4, 52.7, 47.2, 45.7, 41.9, 29.7, 29.5, 26.2, 24.5. HRMS (ESI) calculated for C24H28F3N7NaO+: 510.2205, found 510.2207.


Example 25: Preparation of Compound 25



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 3-isopropoxyphenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 25 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.15 (d, J=1.2 Hz, 1H), 7.36 (t, J=7.9 Hz, 1H), 7.11 (dd, J=8.2, 5.0 Hz, 2H), 7.00-6.95 (m, 1H), 6.70-6.60 (m, 1H), 6.09 (dt, J=16.8, 1.6 Hz, 1H), 5.64 (dt, J=10.6, 1.6 Hz, 1H), 4.60 (q, J=6.0 Hz, 1H), 4.32 (t, J=6.8 Hz, 2H), 3.53 (t, J=6.3 Hz, 4H), 2.38 (s, 4H), 2.30 (t, J=7.6 Hz, 2H), 1.87 (d, J=7.1 Hz, 2H), 1.48 (t, J=7.8 Hz, 2H), 1.25 (dd, J=6.0, 1.3 Hz, 6H), 1.22 (d, J=7.4 Hz, 2H). 13C NMR (100 MHz, MeOD) δ 166.0, 158.6, 158.5, 155.4, 153.7, 144.7, 134.0, 130.2, 127.3, 127.3, 120.1, 116.4, 115.5, 100.0, 97.6, 69.9, 57.6, 52.8, 52.3, 46.4, 45.0, 41.3, 28.9, 25.2, 23.9, 21.0. HRMS (ESI) calculated for C26H35N7NaO2+: 500.2744, found 500.2747.


Example 26: Preparation of Compound 26



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 3-benzyloxyphenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 26 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.37 (s, 1H), 7.49-7.27 (m, 8H), 7.11 (d, J=8.5 Hz, 1H), 6.54 (dd, J=16.8, 10.4 Hz, 1H), 6.28 (d, J=16.8 Hz, 1H), 5.69 (d, J=10.4 Hz, 1H), 5.43 (s, 2H), 5.17 (s, 2H), 4.44 (t, J=7.4 Hz, 2H), 3.62 (d, J=49.9 Hz, 4H), 2.39 (d, J=27.3 Hz, 6H), 2.03-1.93 (m, 2H), 1.38 (s, 2H). 13C NMR (100 MHz, CDCl3) δ 165.3, 159.4, 157.7, 155.4, 154.2, 144.1, 136.6, 134.5, 133.3, 130.6, 128.7, 128.1, 127.7, 127.5, 127.4, 120.9, 116.0, 114.5, 98.2, 70.0, 58.1, 53.3, 52.7, 47.1, 45.7, 41.8, 29.5, 26.2, 24.5, 21.2. HRMS (ESI) calculated for C30H35N7NaO2+: 548.2744, found 548.2747.


Example 27: Preparation of Compound 27



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 2-chloro-5-methoxyphenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 27 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.35 (d, J=4.2 Hz, 1H), 7.43 (s, 1H), 6.99 (dq, J=19.8, 3.2 Hz, 2H), 6.53 (ddd, J=15.6, 10.7, 3.9 Hz, 1H), 6.25 (dd, J=16.9, 3.9 Hz, 1H), 5.80-5.22 (m, 3H), 4.45 (t, J=6.5 Hz, 2H), 3.82 (d, J=4.9 Hz, 3H), 3.68-3.63 (m, 2H), 3.51 (s, 2H), 2.39 (d, J=5.4 Hz, 4H), 2.31 (q, J=6.2, 5.4 Hz, 2H), 1.99 (q, J=6.8 Hz, 2H), 1.53 (q, J=7.1 Hz, 2H), 1.42-1.28 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 165.3, 158.6, 157.7, 155.9, 153.8, 141.1, 132.6, 131.1, 127.7, 127.5, 124.7, 116.9, 99.9, 70.5, 58.2, 55.7, 53.4, 52.7, 47.1, 45.7, 41.9, 29.5, 26.2, 24.5. HRMS (ESI) calculated for C24H30ClN7NaO2+: 506.2042, found 506.2044.


Example 28: Preparation of Compound 28



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar p-fluorophenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 28 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.31 (s, 1H), 7.25 (s, 2H), 6.54 (dd, J=16.8, 10.5 Hz, 1H), 6.29 (dd, J=16.8, 1.7 Hz, 1H), 6.24 (s, 2H), 5.70 (d, J=10.5 Hz, 1H), 4.35 (t, J=7.0 Hz, 2H), 3.69 (t, J=29.6 Hz, 4H), 2.44 (d, J=31.0 Hz, 6H), 1.92 (dd, J=14.9, 7.4 Hz, 2H), 1.58 (s, 2H), 1.35-1.30 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 165.21, 158.54, 157.68, 155.61, 153.68, 141.11, 132.50, 131.04, 127.66, 127.44, 124.68, 116.84, 99.80, 58.07, 55.65, 53.26, 52.63, 47.07, 45.59, 41.74, 29.40, 26.09, 24.40. HRMS (ESI) calculated for C23H28FN7NaO+: 460.2232, found 460.2230.


Example 29: Preparation of Compound 29



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 3-fluoro-4-hydroxyphenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 29 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.34 (s, 1H), 7.72-7.62 (m, 2H), 7.26-7.23 (m, 1H), 6.55 (dd, J=16.8, 10.5 Hz, 1H), 6.28 (dd, J=16.8, 1.9 Hz, 1H), 5.69 (dd, J=10.5, 1.9 Hz, 1H), 4.44 (t, J=7.2 Hz, 2H), 3.68 (s, 2H), 3.51 (d, J=21.5 Hz, 2H), 2.47-2.39 (m, 4H), 2.36-2.31 (m, 2H), 1.99 (dt, J=15.0, 7.5 Hz, 2H), 1.55 (dd, J=15.1, 7.6 Hz, 2H), 1.42-1.33 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 165.30, 162.94, 161.55, 157.73, 157.26, 156.54, 154.10, 119.85, 117.25, 100.41, 100.29, 99.99, 61.49, 57.97, 53.20, 52.53, 47.28, 29.69, 29.65, 29.40, 29.26, 24.72, 24.24. HRMS (ESI) calculated for C23H28FN7NaO2+: 476.2181, found 476.2180.


Example 30: Preparation of Compound 30



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 6-methoxynaphthalene-2-boronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 30 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.37 (d, J=5.6 Hz, 1H), 8.08 (s, 1H), 7.91 (d, J=8.4 Hz, 1H), 7.83 (d, J=8.9 Hz, 1H), 7.77 (dd, J=8.4, 1.6 Hz, 1H), 7.26-7.19 (m, 2H), 6.51 (dd, J=16.8, 10.5 Hz, 1H), 6.31-6.16 (m, 1H), 5.77 (d, J=66.8 Hz, 2H), 5.67 (dd, J=10.5, 1.9 Hz, 1H), 4.47 (t, J=7.2 Hz, 2H), 3.97 (s, 3H), 3.69 (s, 2H), 3.54 (s, 2H), 2.38 (dd, J=21.6, 14.2 Hz, 6H), 2.02 (dt, J=14.8, 7.4 Hz, 2H), 1.63-1.53 (m, 2H), 1.41 (dt, J=15.1, 7.5 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.27, 158.50, 157.93, 155.54, 154.31, 144.47, 134.66, 129.73, 128.92, 128.23, 128.12, 127.81, 127.54, 127.43, 126.28, 119.94, 105.79, 98.49, 58.13, 55.42, 53.27, 52.70, 47.05, 45.55, 41.71, 29.57, 26.08, 24.51. HRMS (ESI) calculated for C28H33N7NaO2+: 522.2588, found 522.2587.


Example 31: Preparation of Compound 31



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar p-nitrophenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 31 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.45-8.36 (m, 3H), 7.92 (d, J=8.8 Hz, 2H), 6.54 (dd, J=16.8, 10.5 Hz, 1H), 6.27 (dd, J=16.9, 2.0 Hz, 1H), 5.90-5.63 (m, 3H), 4.48 (t, J=7.2 Hz, 2H), 3.67 (s, 2H), 3.59-3.50 (m, 2H), 2.42 (t, J=5.1 Hz, 4H), 2.35 (dd, J=8.5, 6.5 Hz, 2H), 2.01 (p, J=7.6 Hz, 2H), 1.63-1.55 (m, 2H), 1.41 (dt, J=11.4, 6.8 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.3, 157.6, 155.9, 154.7, 148.0, 141.7, 139.6, 129.2, 127.8, 127.5, 124.6, 98.4, 77.2, 58.1, 53.4, 52.7, 47.4, 45.7, 41.8, 29.7, 29.5, 26.2, 24.5. HRMS (ESI) calculated for C23H28N8NaO3+: 487.2177, found 487.2179.


Example 32: Preparation of Compound 32



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 3-fluoro-5-methoxyphenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 31 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 7.24 (d, J=2.1 Hz, 2H), 6.99-6.87 (m, 1H), 6.54 (dd, J=16.8, 10.6 Hz, 1H), 6.27 (dd, J=16.8, 1.9 Hz, 1H), 5.80-5.63 (m, 3H), 4.44 (t, J=7.2 Hz, 2H), 3.92 (s, 3H), 3.66 (d, J=12.5 Hz, 2H), 3.54 (s, 2H), 2.45-2.33 (m, 6H), 2.02-1.96 (m, 2H), 1.55 (dd, J=15.0, 7.5 Hz, 2H), 1.37 (dd, J=15.2, 7.2 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.31, 164.85, 164.72, 162.35, 162.23, 157.51, 155.78, 154.50, 127.78, 127.48, 111.59, 111.33, 104.53, 104.28, 98.15, 58.13, 53.38, 52.69, 47.23, 45.66, 41.82, 29.49, 26.17, 24.51. HRMS (ESI) calculated for C24H30FN7NaO2+: 490.2337, found 490.2335.


Example 33: Preparation of Compound 33



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 3,5-difluorophenylboronic acid was used instead of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 33 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.36 (s, 1H), 7.01 (dd, J=8.4, 2.2 Hz, 2H), 6.73 (dt, J=10.5, 2.3 Hz, 1H), 6.55 (dd, J=16.8, 10.6 Hz, 1H), 6.28 (dd, J=16.8, 1.9 Hz, 1H), 5.83 (s, 2H), 5.69 (dd, J=10.5, 1.9 Hz, 1H), 4.44 (t, J=7.2 Hz, 2H), 3.66 (m, J=16.1 Hz, 2H), 3.55 (m, 2H), 2.37 (dd, J=23.0, 15.7 Hz, 6H), 1.98 (dd, J=14.9, 7.5 Hz, 2H), 1.56 (dd, J=14.8, 7.4 Hz, 2H), 1.45-1.36 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 165.28, 162.81, 161.77, 161.65, 157.58, 155.96, 154.41, 127.74, 127.49, 110.07, 110.04, 107.79, 107.57, 102.38, 102.13, 98.25, 58.15, 55.81, 53.35, 52.74, 47.12, 29.51, 24.50. HRMS (ESI) calculated for C23H27F2N7NaO+: 478.2137, found 478.2139.


Example 34: Preparation of Compound 34



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 3,5-bis(trifluoromethyl)phenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 34 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.44 (s, 1H), 8.20 (s, 2H), 7.99 (s, 1H), 6.61-6.51 (m, 1H), 6.28 (d, J=17.0 Hz, 1H), 5.69 (d, J=10.6 Hz, 1H), 4.48 (t, J=7.0 Hz, 2H), 3.64 (s, 4H), 2.39 (d, J=26.1 Hz, 6H), 2.05-1.99 (m, 2H), 1.78 (s, 2H), 1.38 (dd, J=23.0, 12.9 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.3, 157.5, 156.0, 154.8, 140.9, 135.5, 133.2, 132.9, 132.6, 128.5, 127.8, 127.5, 124.4, 122.5, 121.7, 98.4, 58.1, 53.4, 52.7, 47.35 45.7, 41.8, 29.5, 26.2, 24.5. HRMS (ESI) calculated for C25H27F6N7NaO+: 578.2073, found 578.2075.


Example 35: Preparation of Compound 35



embedded image


A specific preparation method was the same as the preparation method of compound 1, except that one of the raw materials was equimolar 3-fluoro-5-trifluoromethylphenylboronic acid, in replacement of 3,5-dimethoxyphenylboronic acid in the preparation method of compound (1-2). NMR test results of the compound 35 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.35 (s, 1H), 7.73 (s, 1H), 7.58 (dd, J=8.7, 2.0 Hz, 1H), 7.40-7.37 (m, 1H), 6.48 (dd, J=16.8, 10.5 Hz, 1H), 6.20 (dd, J=16.8, 1.9 Hz, 1H), 5.61 (dd, J=10.5, 1.9 Hz, 1H), 4.39 (t, J=7.2 Hz, 2H), 3.60 (s, 2H), 3.47 (s, 2H), 2.34 (t, J=5.1 Hz, 4H), 2.30-2.24 (m, 2H), 1.96-1.90 (m, 2H), 1.52-1.47 (m, 2H), 1.32 (t, J=7.6 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 162.0, 161.5, 157.8, 155.6, 154.1, 144.2, 135.0, 129.5, 127.8, 127.7, 106.4, 101.0, 98.2, 58.0, 55.6, 53.3, 52.5, 47.0, 46.0, 42.2, 29.7, 29.5, 26.2, 24.5. HRMS (ESI) calculated for C24H27F4N7NaO+: 528.2105, found 528.2107.


Example 36: Preparation of Compound 36



embedded image


A specific preparation method was the same as the preparation method of compound 10, except that one of the raw materials was equimolar 4,4,4-trifluorocrotonic acid, in replacement of acryloyl chloride in the preparation method of compound (1-3). NMR test results of the compound 36 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.32 (s, 1H), 6.92 (dt, J=15.4, 2.1 Hz, 1H), 6.78 (d, J=2.3 Hz, 2H), 6.73-6.64 (m, 1H), 6.52 (t, J=2.3 Hz, 1H), 4.40 (t, J=7.2 Hz, 2H), 3.82 (s, 6H), 3.65 (t, J=5.2 Hz, 2H), 3.50 (t, J=5.0 Hz, 2H), 2.40 (q, J=4.7 Hz, 4H), 2.32 (t, J=7.5 Hz, 2H), 1.96 (p, J=7.4 Hz, 2H), 1.52 (q, J=7.6 Hz, 2H), 1.36 (q, J=8.2 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 162.3, 161.8, 158.1, 155.8, 154.3, 144.4, 135.3, 129.7, 129.4, 128.0, 127.9, 121.4, 106.6, 101.3, 98.5, 58.3, 55.8, 53.5, 52.7, 47.3, 46.2, 42.5, 29.9, 29.8, 26.4, 24.7. HRMS (ESI) calculated for C26H32F3N7NaO3+: 570.2411, found 570.2413.


Example 37: Preparation of Compound 37



embedded image


A specific preparation method was the same as the preparation method of compound 34, except that one of the raw materials was equimolar 4,4,4-trifluorobutenoic acid in replacement of acryloyl chloride in the preparation method of compound (1-3). NMR test results of the compound 37 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.43 (d, J=2.3 Hz, 1H), 8.20 (s, 2H), 7.99 (s, 1H), 6.94 (d, J=15.5 Hz, 1H), 6.72 (dt, J=14.9, 6.8 Hz, 1H), 4.48 (t, J=7.0 Hz, 2H), 3.69 (s, 2H), 3.54 (s, 2H), 2.41 (d, J=31.2 Hz, 6H), 2.02 (q, J=7.8 Hz, 2H), 1.59 (s, 2H), 1.44-1.26 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 164.1, 162.1, 161.6, 157.4, 155.9, 154.7, 141.3, 136.6, 127.7, 121.0, 118.9, 118.7, 113.4, 113.2, 98.2, 58.0, 53.3, 52.5, 47.2, 45.9, 42.2, 29.7, 29.5, 26.1, 24.5, 14.1. HRMS (ESI) calculated for C26H26F9N7NaO+: 646.1947, found 646.1947.


Example 38: Preparation of Compound 38



embedded image


A specific preparation method was the same as the preparation method of compound 35, except that one of the raw materials was equimolar 4,4,4-trifluorobutenoic acid, in replacement of acryloyl chloride in the preparation method of compound (1-3). NMR test results of the compound 38 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.43 (d, J=2.3 Hz, 1H), 8.20 (s, 2H), 7.99 (s, 1H), 6.94 (d, J=15.5 Hz, 1H), 6.71 (dq, J=14.2, 6.7 Hz, 1H), 4.48 (t, J=7.0 Hz, 2H), 3.69 (s, 2H), 3.54 (s, 2H), 2.41 (d, J=31.2 Hz, 6H), 2.01 (t, J=7.6 Hz, 2H), 1.59 (s, 2H), 1.48-1.27 (m, 2H). 13C NMR (100 MHz, CDCl3) δ 162.0, 155.2, 154.6, 142.9, 133.2, 132.1, 132.1, 129.4, 129.0, 128.6, 128.5, 127.9, 121.3, 120.8, 111.6, 105.6, 58.1, 53.3, 52.6, 46.9, 46.0, 42.3, 29.5, 26.3, 24.5, 22.1. HRMS (ESI) calculated for C26H26F9N7NaO+: 646.1947, found 646.1947.


Example 39: Preparation of Compound 39



embedded image


A specific preparation method was the same as the preparation method of compound 10, except that one of the raw materials was equimolar trans-4-dimethylaminocrotonic acid, in replacement of acryloyl chloride in the preparation method of compound (1-3). NMR test results of the compound 39 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.38 (s, 1H), 6.81 (d, J=2.3 Hz, 2H), 6.56 (t, J=2.3 Hz, 1H), 5.60 (s, 2H), 4.43 (t, J=7.2 Hz, 2H), 3.86 (s, 6H), 3.67 (t, J=5.1 Hz, 2H), 3.59 (t, J=5.1 Hz, 2H), 3.49 (s, 1H), 2.45 (t, J=5.1 Hz, 4H), 2.33 (t, J=7.4 Hz, 2H), 1.96 (d, J=7.5 Hz, 2H), 1.50-1.35 (m, 4H). 13C NMR (100 MHz, CDCl3) δ 161.5, 161.5, 157.7, 155.9, 144.0, 135.1, 106.4, 101.0, 100.0 98.3, 58.1, 55.6, 53.1, 52.4, 52.3, 49.4, 47.1, 45.8, 43.4, 43.3, 43.2, 37.4, 29.6, 26.9, 26.5. HRMS (ESI) calculated for C25H31N7NaO3+: 500.2831, found 500.2833.


Example 40: Preparation of Compound 40



embedded image


A specific preparation method was the same as the preparation method of compound 10, except that one of the raw materials was equimolar crotonic acid, in replacement of acryloyl chloride in the preparation method of compound (1-3). NMR test results of the compound 40 were as follows:



1H NMR (400 MHz, CDCl3) δ 8.31 (s, 1H), 6.88-6.73 (m, 3H), 6.52 (t, J=2.3 Hz, 1H), 6.20 (dq, J=15.0, 1.7 Hz, 1H), 4.39 (t, J=7.2 Hz, 2H), 3.82 (s, 6H), 3.62 (d, J=8.1 Hz, 2H), 3.56-3.43 (m, 2H), 2.36 (t, J=5.1 Hz, 4H), 2.29 (dd, J=8.7, 6.4 Hz, 2H), 2.01-1.91 (m, 2H), 1.83 (dd, J=6.9, 1.7 Hz, 3H), 1.52 (t, J=7.6 Hz, 2H), 1.36 (ddd, J=15.3, 9.1, 5.4 Hz, 2H). 13C NMR (100 MHz, CDCl3) δ 165.5, 161.5, 158.0, 155.7, 154.1, 144.1, 141.5, 135.1, 121.4, 119.9, 106.4, 101.1, 98.2, 60.4, 58.2, 55.5, 53.5, 53.4, 52.8, 47.0, 45.5, 41.8, 29.6, 26.2, 24.5, 18.2. HRMS (ESI) calculated for C26H35N7NaO3+: 516.2694, found 516.2696.


Example 41 Enzyme Activity Test

In the present disclosure, the homogeneous time-resolved fluorescence (HTRF) technology was used to evaluate an inhibitory effect of a compound on the four subtypes FGFR1, FGFR2, FGFR3, and FGFR4. FGFR1, FGFR2, FGFR3, and FGFR4 prokaryotic expression vectors were first constructed; and when the prokaryotic expression vectors were identified as correct, FGFR proteins were expressed and purified on a large scale in an Escherichia coli (E. coli) system, and protein concentrations were determined. Resulting proteins were stored in aliquots. Before an enzyme activity test was started, cisbio HTRF KinEA (62TK0PEB) was used to pre-dilute each component required in an enzyme activity system with an enzyme activity buffer to a required working concentration. A 384-well plate (66PL384025) was prepared, 5 μL of a protein solution, 1 μL of a compound, and 2 μL of a substrate were added to each well, and 2 μL of ATP was finally added to initiate a reaction. Three parallel experiments were set for each concentration. In the blank control group, 1 μL of the compound was replaced with 1 μL of dimethyl sulfoxide (DMSO); and in the positive control group, the positive drug AZD4547 was used instead, and the other conditions remained unchanged. The 384-well plate was sealed and incubated at room temperature for about 1 h. After the incubation was completed, 5 μL of a lanthanide-labeled phosphorylated substrate antibody (a donor) and 5 μL of a streptavidin-labeled XL665 (a receptor) were added to each well to stop the reaction, and the plate was further incubated at room temperature for about 1 h in the dark. Finally, the TECAN infinite M1000PRO multi-function microplate reader was used to detect a fluorescence signal, an inhibition rate was calculated, and an IC50 value was fitted with GraphPad Prism 7.0.


Results showed that the compounds 1 to 40 could inhibit the protein activity of FGFR1/2/3/4 to varying degrees.









TABLE 1







Structure-activity relationship (SAR) studies based on enzyme activity results




embedded image
















Compound



Enzyme activity (IC50/nM)














No.
Ar
Linker
R
FGFR1
FGFR2
FGFR3
FGFR4




















1


embedded image




embedded image


H
 315
540
520
1921





2



embedded image



 818
666
525
>5000





3



embedded image



 433
424
371
2730





4



embedded image



 615
641
521
>5000





5



embedded image



 741
1210
580
1780





6



embedded image



 790
1130
769
>5000





7



embedded image



 372
455
335
1610





8



embedded image



 323
351
414
40





9



embedded image



  36.0
27.4
22.5
4210





10



embedded image



  3.2
1.4
2.7
3270





11



embedded image



  12.9
11.2
11.3
3207





12



embedded image



  5.9
2.2
3.4
>5000





13


embedded image




embedded image



 476
78 
875
2709





14


embedded image




 2109
1864
344
>5000





15


embedded image




>5000
3121
>5000
>5000





16


embedded image




 1353
2511
1321
>5000





17


embedded image




 3523
4111
>5000
>5000





18


embedded image




>5000
>5000
>5000
>5000





19


embedded image




>5000
>5000
>5000
>5000





20


embedded image




>5000
>5000
>5000
>5000





21


embedded image




 866
954
1978
>5000





22


embedded image




 324
231
523
>5000





23


embedded image




 277
223
486
4910





24


embedded image




 1877
>5000
>5000
3903





25


embedded image




>5000
>5000
>5000
2246





26


embedded image




 1501
2345
>5000
>5000





27


embedded image




 554
763
731
2723





28


embedded image




 185
337
321
2987





29


embedded image




 417
560
318
2580





30


embedded image




>5000
>5000
>5000
>5000





31


embedded image




>5000
>5000
>5000
>5000





32


embedded image




 118
133
132
>5000





33


embedded image




 790
>10
>10
4112





34


embedded image




 133
165
115
3921





35


embedded image




  14.1
29.3
13.2
4102





36


embedded image



CF3
  0.7
0.7
0.9
809





37


embedded image




  9.9
12.1
10.2
>5000





38


embedded image




 101
65
97
2401





39 40


embedded image



(CH3)2NCH2 CH3
  13.8   16.6
37.5 26.3
15.5 12.4
>5000 >5000















AZD4547
NA
  1.1
2.2
1.8
660









Example 42 Cell Proliferation Assay

In the present disclosure, the compounds 10 and 36 were selected, and the methyl thiazolyl tetrazolium (MTT) colorimetric method was used to evaluate the proliferation inhibition effects of the compounds 10 and 36 on various tumor cells. Tumor cells in a logarithmic growth phase were collected through trypsinization and resuspended in 1 mL of a fresh medium, and a small amount of a resulting suspension was taken, diluted, and subjected to cell counting with a hemocytometer. According to the cell growth rate, tumor cells were inoculated into a 96-well plate at a density of 3,000 cells/well to 5,000 cells/well, and then cultivated in an incubator for 24 h. The tumor cells were treated with the compounds 10 and 36 at 8 concentrations, with three replicate wells for each concentration, and then incubated for 96 h. After the incubation was completed, 10 μL of an MTT solution (5 mg/mL) was added to each well, and the plate was tapped for thorough mixing and then further incubated in an incubator for 3 h to 4 h. After the incubation was completed, the liquid in the well plate was carefully pipetted and removed, and then 100 μL of a DMSO solution was added to each well. Programs of a microplate reader were set to determine the absorbance values at 490 nm and 570 nm respectively, a proliferation inhibition rate at each concentration was calculated according to a formula, and the Graphpad Prism 7 software was finally used for data processing to calculate IC50.


The results (Table 1) showed that the compounds 10 and 36 significantly inhibited the proliferation of human squamous cell lung carcinoma cell NCI-H1581 (FGFR1 amplification) and human gastric cancer cell SNU-16 (FGFR2 amplification) and inhibited the proliferation of human hepatoma cell SK-hep-1 (FGFR4 amplification) to some degree, but exhibited no obvious inhibitory effect on tumor cells with normal FGFR expression, indicating that the compounds 10 and 36 had strong selectivity.









TABLE 2







Anti-proliferation activities of the compound 36 for specific cancer cell lines









IC50/μM













NCI-H1581
SNU-16
SK-hep-1





FGFR1
FGFR2
FGFR4


Compound
amplification
amplification
amplification
Huh-7
A549





AZD4547
0.042 ± 0.002
0.006 ± 0.001
2.78 ± 0.069
>10
>10


10
0.051 ± 0.003
0.037 ± 0.005
2.86 ± 0.250
>10
>10


36
0.055 ± 0.008
0.043 ± 0.006
3.05 ± 0.120
>10
>10









Example 43 Inhibition of the Compounds 10 and 36 on FGF/FGFR and Downstream Signaling Pathways Thereof

To further elucidate the influence of the compounds 10 and 36 on FGF/FGFR signaling, the influence of the compounds on FGFR and downstream signaling protein phosphorylation was verified by western blot (WB). Each of human squamous cell lung carcinoma cells NCI-H1581 and human gastric cancer cells SNU-16 in a logarithmic growth phase were collected through trypsinization and resuspended in 1 mL of a fresh medium, and a small volume of a resulting tumor cell suspension was taken, diluted, and subjected to cell counting with a hemocytometer. A corresponding volume of the tumor cell suspension was taken and inoculated into a 6-well plate at a density of 3×105 cells/well, and cultivated in an incubator for 24 h. After the cells were completely adherence, the used medium was pipetted and removed, fresh media with the compounds 10 and 36 at different concentrations were added, and the plate was incubated in an incubator for 12 h. After the incubation was completed, a culture supernatant was pipetted and removed, and the plate was washed three times with a pre-cooled 1×PBS solution to completely pipet and remove the residual solution; 60 μL of an RIPA lysis buffer was added to each well, and cells were gently scraped off with a cell scraper; a resulting lysis buffer was transferred to a 1.5 mL EP tube, subjected an ice bath for 10 min, and centrifuged at 14,000 rpm for 10 min, a resulting supernatant was pipetted into a new 1.5 mL EP tube, and a small amount of the supernatant was pipetted for protein content determination; and a corresponding volume of 5×loading buffer was added to the remaining supernatant, and a resulting mixture was vortexed for thorough mixing and subjected a metal bath at 100° C. for 10 min. According to a determined protein content, a corresponding loading amount was calculated at 30 μg of protein per well. Proteins were isolated by 8% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), the isolated proteins were transferred to a polyvinylidene fluoride (PVDF) membrane, and stained with Ponceau S, and the PDVF membrane with proteins was cut according to a molecular weight of a target protein, rinsed with a 1×TBST solution to remove Ponceau S, and blocked with 5% skimmed milk powder for 30 min. The PDVF membrane was washed three times with a 1× TBST solution, a PDVF membrane with the target protein band was placed in an incubation box, a corresponding primary antibody incubation solution was added, and the PDVF membrane was incubated at 4° C. overnight. After the primary antibody incubation was completed, the membrane was washed three times with a 1× TBST solution, a corresponding secondary antibody incubation solution was added, and the membrane was incubated at room temperature for 1.5 h. After the incubation was completed, the membrane was washed three times with a 1× TBST solution and subjected to color development with a hypersensitive horseradish peroxidase (HRP) chemiluminescence kit.


As shown in FIGS. 1A, 1B, 2A and 2B, the compounds 10 and 36 not only significantly inhibited the phosphorylation of FGFR1 in NCI-H1581 cells and the phosphorylation of FGFR2 in SNU-16 cells, but also inhibited the activation of downstream PLCγ, AKT, and ERK in a dose-dependent manner. In a word, the compounds 10 and 36 can strongly inhibit FGF/FGFR and downstream signaling pathways in vitro.


Example 44 Significant Inhibition of the Compounds 10 and 36 on Tumor Growth in Mice

In order to evaluate an anti-tumor effect of the compounds 10 and 36 in vivo, a mouse subcutaneous xenograft model was established with human squamous cell lung carcinoma cells NCI-H1581 with high FGFR1 expression. Cells in a logarithmic growth phase were collected through trypsinization, washed three times with 1×PBS. A resulting cell precipitation was diluted to 1×108 cells/mL with a resuspending solution (1640 medium:Matrigel=1:1), and inoculated into inferior extremity of armpits of anterior limbs of 5-6 week-old female BALB/c Nude mice at 5×106 cells/mouse. When a tumor volume grew to 50 mm3 to 100 mm3, the mice were randomly divided into three groups (control group, 50 mg/kg, and 100 mg/kg), with 6 mice in each group. The compound 10 was administered orally every day, and the compound 36 was intraperitoneally injected every day. The tumor volume and mouse body weight were measured. The mice was treated after 26 d of administration, that a tumor tissue was dissected and fixed in a formalin solution for later use.


As shown in FIGS. 3A, 3B, 3C, 3D, 4A, 4B, 4C, 4D and 4E, the compounds 10 and 36 inhibited the proliferation of NCI-H1581 cells in mice in a dose-dependent manner, with an inhibition rate of 72% in the high-dose group; inhibited the phosphorylation activation of FGFR1 in a tumor tissue; and did not lead to an obvious weight loss, indicating that the compounds 10 and 36 were well tolerated in vivo at all doses.


In conclusion, the present disclosure optimizes 2H-pyrazolo[3,4-d]pyrimidine to obtain novel derivatives thereof (compounds 10 and 36), and the compounds 10 and 36 are served as effective and selective inhibitors for FGFR1, FGFR2, and FGFR3, which exhibit an irreversible binding effect to a target protein. The compounds are leading compounds that can not only inhibit FGF/FGFR and downstream signaling pathways thereof at low concentrations, but also exhibit significant anti-proliferation effects on the NCI-H1581 cancer cell line in vitro and in vivo. In addition, the compounds 10 and 36 show low toxicity and prominent PK properties, and are currently identified as potential drug candidates.


The above are merely examples of the present disclosure, and are not intended to limit the present disclosure. Any modification, equivalent substitution, and improvement fall within the spirit and principle of the present disclosure should be included in the claimed scope of the present disclosure.


REFERENCES



  • (1) Turner, N.; Grose, R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 2010, 10, 116-129.

  • (2) Carter, E. P.; Fearon, A. E.; Grose, R. P. Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends Cell Biol. 2015, 25, 221-233.

  • (3) Touat, M.; Ileana, E.; Postel-Vinay, S.; Andre, F.; Soria, J. C. Targeting FGFR signaling in cancer. Clin. Cancer Res. 2015, 21, 2684-2694.

  • (4) Dieci, M. V; Arnedos, M.; Andre, F.; Soria, J. C. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discovery 2013, 3, 264-279.

  • (5) Hagel, M.; Miduturu, C.; Sheets, M.; Rubin, N.; Weng, W.; Stransky, N.; Bifulco, N.; Kim, J. L.; Hodous, B.; Brooijmans, N.; Shutes, A.; Winter, C.; Lengauer, C.; Kohl, N. E.; Guzi, T. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway. Cancer Discovery 2015, 5, 424-437.

  • (6) Babina, I. S.; Turner, N. C. Advances and challenges in targeting FGFR signalling in cancer. Nat. Rev. Cancer 2017, 17, 318-332.

  • (7) Renhowe, P. A.; Pecchi, S.; Shafer, C. M.; Machajewski, T. D.; Jazan, E. M.; Taylor, C.; Antonios-McCrea, W.; McBride, C. M.; Frazier, K.; Wiesmann, M.; Lapointe, G. R.; Feucht, P. H.; Warne, R. L.; Heise, C. C.; Menezes, D.; Aardalen, K.; Ye, H.; He, M.; Le, V; Vora, J.; Jansen, J. M.; Wernette-Hammond, M. E.; Harris, A. L. Design, structure-activity relationships and in vivo characterization of 4-amino-3-benzimidazol-2-ylhydroquinolin-2-ones: a novel class of receptor tyrosine kinase inhibitors. J. Med. Chem. 2009, 52, 278-292.

  • (8) Bello, E.; Colella, G.; Scarlato, V; Oliva, P.; Berndt, A.; Valbusa, G.; Serra, S. C.; D'Incalci, M.; Cavalletti, E.; Giavazzi, R.; Damia, G.; Camboni, G. E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res. 2011, 71, 1396-1405.

  • (9) Roth, G. J.; Heckel, A.; Colbatzky, F.; Handschuh, S.; Kley, J.; Lehmann-Lintz, T.; Lotz, R.; Tontsch-Grunt, U.; Walter, R.; Hilberg, F. Design, synthesis, and evaluation of indolinones as triple angiokinase inhibitors and the discovery of a highly specific 6-methoxycarbonyl-substituted indolinone (BIBF 1120). J. Med. Chem. 2009, 52, 4466-4480.

  • (10) Gozgit, J. M.; Wong, M. J.; Moran, L.; Wardwell, S.; Mohemmad, Q. K.; Narasimhan, N. I.; Shakespeare, W. C.; Wang, F.; Clackson, T.; Rivera, V. M. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol. Cancer Ther. 2012, 11, 690-699.

  • (11) Gavine, P. R.; Mooney, L.; Kilgour, E.; Thomas, A. P.; Al-Kadhimi, K.; Beck, S.; Rooney, C.; Coleman, T.; Baker, D.; Mellor, M. J.; Brooks, A. N.; Klinowska, T. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012, 72, 2045-2056.

  • (12) Guagnano, V; Furet, P.; Spanka, C.; Bordas, V.; Le Douget, M.; Stamm, C.; Brueggen, J.; Jensen, M. R.; Schnell, C.; Schmid, H.; Wartmann, M.; Berghausen, J.; Drueckes, P.; Zimmerlin, A.; Bussiere, D.; Murray, J.; Graus Porta, D. Graus Porta, D. Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase. J. Med. Chem. 2011, 54, 7066-7083.

  • (13) Zhao, G.; Li, W. Y.; Chen, D.; Henry, J. R.; Li, H. Y.; Chen, Z.; Zia-Ebrahimi, M.; Bloem, L.; Zhai, Y.; Huss, K.; Peng, S. B.; McCann, D. J. A novel, selective inhibitor of fibroblast growth factor receptors that shows a potent broad spectrum of antitumor activity in several tumor xenograft models. Mol. Cancer Ther. 2011, 10, 2200-2210.

  • (14) Perera, T. P. S.; Jovcheva, E.; Mevellec, L.; Vialard, J.; De Lange, D.; Verhulst, T.; Paulussen, C.; Van De Ven, K.; King, P.; Freyne, E.; Rees, D. C.; Squires, M.; Saxty, G.; Page, M.; Murray, C. W.; Gilissen, R.; Ward, G.; Thompson, N. T.; Newell, D. R.; Cheng, N.; Xie, L.; Yang, J.; Platero, S. J.; Karkera, J. D.; Moy, C.; Angibaud, P.; Laquerre, S.; Lorenzi, M. V. Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol. Cancer Ther. 2017, 16, 1010-1020.

  • (15) Zhou, W.; Hur, W.; McDermott, U.; Dutt, A.; Xian, W.; Ficarro, S. B.; Zhang, J.; Sharma, S. V; Brugge, J.; Meyerson, M.; Settleman, J.; Gray, N. S. A structure-guided approach to creating covalent FGFR inhibitors. Chem. Biol. 2010, 17, 285-295.

  • (16) Tan, L.; Wang, J.; Tanizaki, J.; Huang, Z.; Aref, A. R.; Rusan, M.; Zhu, S. J.; Zhang, Y; Ercan, D.; Liao, R. G.; Capelletti, M.; Zhou, W.; Hur, W.; Kim, N.; Sim, T.; Gaudet, S.; Barbie, D. A.; Yeh, J. R. J.; Yun, C. H.; Hammerman, P. S.; Mohammadi, M.; Janne, P. A.; Gray, N. S. Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc. Natl. Acad. Sci. U.S.A. 2014, 111, E4869-E4877.

  • (17) Brown, W. S.; Tan, L.; Smith, A.; Gray, N. S.; Wendt, M. K. Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer. Mol. Cancer Ther. 2016, 15, 2096-2106.

  • (18) Brameld, K. A.; Owens, T. D.; Verner, E.; Venetsanakos, E.; Bradshaw, J. M.; Phan, V. T.; Tam, D.; Leung, K.; Shu, J.; LaStant, J.; Loughhead, D. G.; Ton, T.; Karr, D. E.; Gerritsen, M. E.; Goldstein, D. M.; Funk, J. O. Discovery of the irreversible covalent FGFR inhibitor 8-(3-(4-acryloylpiperazin-1-yl)propyl)-6-(2,6-di chloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the treatment of solid tumors. J. Med. Chem. 2017, 60, 6516-6527.

  • (19) Wang, Y; Dai, Y; Wu, X.; Li, F.; Liu, B.; Li, C.; Liu, Q.; Zhou, Y.; Wang, B.; Zhu, M.; Cui, R.; Tan, X.; Xiong, Z.; Liu, J.; Tan, M.; Xu, Y.; Geng, M.; Jiang, H.; Liu, H.; Ai, J.; Zheng, M. Discovery and Development of a Series of Pyrazolo[3,4-d]pyridazinone Compounds as the Novel Covalent Fibroblast Growth Factor Receptor Inhibitors by the Rational Drug Design. J. Med. Chem. 2019, 62, 7473-7488.

  • (20) Wang, Y; Li, L.; Fan, J.; Dai, Y.; Jiang, A.; Geng, M.; Ai, J.; Duan, W. Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors. J. Med. Chem. 2018, 61, 9085-9104.

  • (21) Li, X.; Guise, C. P.; Taghipouran, R.; Yosaatmadja, Y.; Ashoorzadeh, A.; Paik, W.; Squire, C. J.; Jiang, S.; Luo, J.; Xu, Y; Tu, Z.; Lu, X.; Ren, X.; Patterson, A. V; Smaill, J. B.; Ding, K. 2-Oxo-3,4-dihydropyrimido[4,5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. Eur. J. Med. Chem. 135, 2017, 531-543.


Claims
  • 1. A compound of formula I or a pharmaceutically acceptable salt thereof:
  • 2. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the Ar is
  • 3. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the R is H, CF3, (CH3)2NCH2, or CH3.
  • 4. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the Linker is
  • 5. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is one selected from the group consisting of compound 1 to compound 40:
  • 6. A method for preparing the compound or the pharmaceutically acceptable salt thereof according to claim 1, with a synthetic route as follows:
  • 7. The method according to claim 6, comprising the following steps: subjecting a compound with a structure shown in formula a and a compound with a structure shown in formula b to a Mitsunobu reaction at room temperature for 4 h to obtain a compound with a structure shown in formula c;subjecting the compound with the structure shown in formula c and a compound with a structure shown in formula d to a Suzuki coupling reaction at 80° C. to obtain a compound with a structure shown in formula e;subjecting the compound with the structure shown in formula e and trifluoroacetic acid (TFA) to a deprotection reaction at 0° C. to obtain a compound with a structure shown in formula f; andsubjecting the compound with the structure shown in formula f to an acylation reaction at room temperature to obtain the compound with a structure shown in formula I;
  • 8-15. (canceled)
  • 16. A method for treating a cancer, comprising the following step: administering an anti-cancer drug to a patient through oral administration or intraperitoneal injection,wherein the anti-cancer drug comprises the compound or the pharmaceutically acceptable salt thereof according to claim 1.
  • 17. The method according to claim 16, wherein the anti-cancer drug comprises the compound 10 or the compound 36.
  • 18. The method according to claim 17, wherein the anti-cancer drug is administered at a dose of 50 mg/kg or 100 mg/kg; and the dose is calculated according to a dosage of the compound 10 or the compound 36.
  • 19. The method according to claim 17, wherein when the anti-cancer drug comprises the compound 10, the anti-cancer drug is administered orally.
  • 20. The method according to claim 17, wherein when the anti-cancer drug comprises the compound 36, the anti-cancer drug is administered through intraperitoneal injection.
Priority Claims (1)
Number Date Country Kind
202011483614.1 Dec 2020 CN national
CROSS REFERENCE TO RELATED APPLICATIONS

The present disclosure is a national phase application of PCT/CN2021/120046 filed Sep. 24, 2021, which claims priority to the Chinese Patent Application 202011483614.1 filed to the China National Intellectual Property Administration (CNIPA) on Dec. 16, 2020 and entitled “COMPOUND, PREPARATION METHOD THEREOF, AND USE THEREOF IN PREPARATION OF ANTI-CANCER DRUG”, which is incorporated herein by reference in its entirety.

PCT Information
Filing Document Filing Date Country Kind
PCT/CN2021/120046 9/24/2021 WO